A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating
early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified
Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and
well tolerated in this study and demonstrate therapeutic benefit in this patient population.